Smart Immune

Smart Immune is a French biotechnology startup with a mission to revolutionize treatment outcomes for cancer and infectious diseases. Founded in 2017, the company is focused on developing ProTcell, a groundbreaking thymus-empowered T cell progenitor platform. This innovative technology aims to rapidly fortify the immune system, offering next-generation allogeneic T cell therapies. Smart Immune's flagship product, SMART101, is currently undergoing Phase I/II clinical trials for cancer patients with AML and ALL, as well as for SCID in the EU and the US. Additionally, the company is leveraging its ProTcell platform to create gene-modified T cell progenitor therapies, including off-the-shelf CAR T treatments.

With its headquarters in Paris, France, Smart Immune has established strategic collaborations with leading institutions in the US and Europe. The company recently secured a significant $5.00M grant investment on 16 April 2023, with the prestigious backing of the Bill & Melinda Gates Foundation. Smart Immune's focus on leveraging cutting-edge biotechnology to address critical healthcare challenges positions it as a promising player in the biotechnology, health care, and life sciences industries.

The company's pioneering approach and strong partnerships underscore its potential to deliver impactful solutions in the fields of hematology and immune-oncology. Smart Immune's innovative platform and ongoing clinical trials highlight its commitment to advancing the frontier of immunotherapy, making it an intriguing prospect for potential investors seeking to support groundbreaking advancements in the biotechnology sector.